ULTRA 1, 2, 3 Demonstrate Safety and Efficacy of Adalimumab in Ulcerative Colitis

ULTRA 1, 2, 3 Demonstrate Safety and Efficacy of Adalimumab in Ulcerative Colitis
Three clinical trials — one an open-label extension study, evaluating adalimumab (Humira) in patients with moderately to severely active ulcerative colitis — were recently reviewed in an article from collaborators at Icahn School of Medicine at Mt Sinai, AbbVie, and other gastroenterology-focused institutions. Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab (ULTRA) 1, 2, and open-extension

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *